In the current study, initiation of the most prescribed TNF-α antagonist-Etanercept led to significantly higher numbers of RA-related outpatient visits, but lower numbers of emergency room visits and hospitalization days among RA patients. This evidence concerns the gene TNF and rheumatoid arthritis.